
    
      This is a Phase 2 study designed to evaluate the safety and efficacy of ABT-126 in treating
      cognitive deficits in subjects with a diagnosis of schizophrenia. Eligible subjects will take
      study drug as an add-on treatment to their ongoing antipsychotic treatment regimen.
    
  